GE HealthCare has announced the availability of MIM ComboTherapy GYN HDR/EBRT,[ii] a solution designed to help clinicians plan and evaluate complex radiation therapy treatments for gynecologic cancers with enhanced precision and confidence.
Gynecologic cancers, including cervical and uterine cancers, are often treated using a combination of radiation therapy approaches – most commonly external beam radiation therapy (EBRT) and high-dose-rate (HDR) brachytherapy. While this combination can be highly effective, it also presents a significant clinical challenge: each treatment contributes to the total radiation dose a patient receives, and clinicians must carefully account for prior doses to safely and effectively plan subsequent therapy.
“For far too long, women’s health has not received the focused attention and innovation it deserves – now is the time to intentionally prioritize the unique health needs of women and girls at every stage of life,” shares Shari Manuel, Sales Vice President, U.S. and Canada Imaging, GE HealthCare. “That gap is especially evident in the treatment of gynecologic cancers, where clinicians have historically had to rely on approximations when evaluating cumulative radiation dose – limiting our ability to fully optimize care. Innovations like MIM ComboTherapy GYN HDR/EBRT represent an important step forward, offering a more complete, patient-specific view of dose distribution across therapies. By enabling more personalized, data-driven decision-making, these advances have the potential to improve both treatment outcomes and quality of life for women bravely fighting these cancers.”
GE HealthCare’s new MIM ComboTherapy GYN HDR/EBRT addresses this need by providing a comprehensive, visual and quantitative approach to dose summation across treatment modalities – helping enable clinicians to better understand how radiation doses from multiple therapies interact within the patient’s anatomy, and support more informed clinical decision-making.
At the core of the technology is advanced 3D dose summation, incorporating both biological effective dose (BED) and Equivalent Dose in 2 Gy fractions (EQD2), enabling clinicians to assess the biological impact of combined treatments more accurately. By clearly visualizing areas of highest dose accumulation – often referred to as “hotspots” – clinicians can more effectively evaluate treatment plans and optimize therapy delivery.
The solution also includes qualitative and quantitative tools to validate the accuracy of deformable image registration, helping ensure that doses from prior treatments are correctly mapped onto current patient anatomy. This capability is particularly important in gynecologic cases, where anatomical variations – such as those caused by HDR applicators – can complicate treatment planning.
“MIM ComboTherapy GYN HDR/EBRT represents an important step forward in helping clinicians confidently plan complex combination therapies,” says J Anders, General Manager, MIM, GE HealthCare. “By providing a clearer understanding of the total radiation dose a patient receives across treatments, this solution helps clinicians make more informed decisions. As cancer care continues to move toward more personalized, data-driven approaches, innovations like this can play an important role in helping improve treatment planning and outcomes for women undergoing radiation therapy.”
Early clinical evaluations suggest that advanced deformable registration and spatial dose mapping approaches – like those supported by MIM – can provide a clinically viable framework for assessing dose accumulation in gynecologic combination therapy, enabling greater confidence in treatment planning decisions.
The technology is part of the MIM Software portfolio within GE HealthCare’s radiation oncology ecosystem and is designed to integrate seamlessly into existing clinical workflows. With standardized processes, automation, and vendor-neutral compatibility across treatment planning systems, MIM ComboTherapy helps streamline plan preparation while maintaining flexibility for diverse clinical environments.
[i] Johns Hopkins Medicine, “Gynecologic Cancers,” accessed April 14, 2026, https://www.hopkinsmedicine.org/health/conditions-and-diseases/gynecologic-cancers.
[ii] MIM ComboTherapy™ GYN HDR/EBRT is available for sale in the United States. Not available in all regions or markets.
